Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.47 |
| ▸ | INSR | P06213 | 3/20 | 0.47 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503695 | 1.00 | CDK7 (0.48) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL29400320 | 0.88 | CDK7 (0.60) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL11916362 | 0.88 | CDK7 (0.60) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL22788897 | 0.86 | CDK7 (0.45) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL30173407 | 0.85 | IGF1R (0.49) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL22246100 | 0.85 | MAP4K1 (0.48) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL13832181 | 0.85 | IGF1R (0.49) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL23154179 | 0.84 | ALK (0.40) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL24179108 | 0.84 | ALK (0.39) | CDK7CDK9ALKINSRIGF1R | |
| SCHEMBL28587033 | 0.84 | CDK7 (0.47) | CDK7CDK9ALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677680-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-113302196-B | EGFR inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4137484-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-113677680-A | EGFR inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-113302196-A | EGFR inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020200191-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020147702-A1 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-07-23 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | CDK7 56/4885CDK9 36/4885ALK 293/4885 |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | CDK7 52/4885CDK9 39/4885ALK 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.